OptiBiotix Health PLC Exclusive licence agreement for OptiBiome(R) (1042I)
March 31 2020 - 1:00AM
UK Regulatory
TIDMOPTI
RNS Number : 1042I
OptiBiotix Health PLC
31 March 2020
Opti B i otix Health plc
( "Opti Bi o t ix" or the "Company")
Exclusive licence agreement for OptiBiome(R) with OptiPharm Pty
Ltd.
OptiBi otix Health p lc (AI M : OPTI), a life sciences busi ness
d e vel o ping co m p o u n ds to tack le o besit y, high
choleste r ol, diabetes and skincare, a nn o unces it has
entered into an exclusive licence agreement for the use of its
OptiBiome(R) weight management ingredient with OptiPharm Pty Ltd.
("OptiPharm").
OptiBiotix registered OptiBiome(R) as an alternative trademark
to SlimBiome(R) to support the sale of its SlimBiome(R) ingredient
in countries in which an implied health claim cannot be made (e.g.
Thailand). The terms of this exclusive licence agreement grant
OptiPharm exclusive use of the OptiBiome(R) trademark in over 20
markets including Australia, parts of Asia, New Zealand, Middle
East, Gulf States and North America. Market exclusivity is linked
to minimum order quantities.
OptiPharm ( https://www.optipharm.com ) is a privately owned
Australian company currently in its 24 (th) year of operation.
OptiPharm specialises in weight management, nutrition and infant
formul a and their products are produced in state of the art
Australian manufacturing facilities that are GMP qualified and
HACCP certified (a risk based system which introduces controls at
critical points of the manufacturing process).
OptiPharm's flagship brand , Optislim , is the No. 1 Australian
weight management brand incorporating shakes, soups and bars
available as Total (Very Low Calorie Diet) or Partial (Low Calorie
Diet) Meal Replacements. Optislim is enjoyed by consumers
throughout Australia, New Zealand, China, shortly the Middle East
and the UAE, and is poised for release throughout South East Asia
and North America. Company-owned trademarked brands include:
-- Optislim(TM) - (weight management meal replacements,
including shakes, chocolate bars & soups)
www.optislim.com.au
-- isustain(TM) - (nutritional meal replacements for Adults,
Children & Diabetics) www.isustain.net.au
-- OPTI GOLD(TM) - (infant formula) www.optigold.com.au
Garry McDonald, Managing Director of OptiPharm, commented: "We
are delighted to have completed negotiations with OptiBiotix for
access to their patented ingredient OptiBiome (R) for exclusive use
in over 20 markets globally. In these troubling times & with
clinical research identifying a link between excess weight and
one's immune system, OptiPharm are continually searching for
innovative ingredients such as OptiBiome (R) , to enhance our
Optislim product formulations. We look forward to working with
OptiBiotix to deliver to our customers the latest in innovation,
value and quality."
Dr. Fred Narbel, Managing Director of OptiBiotix's prebiotics
division , c o mmented: "We are very pleased to enter into a
commercial agreement with OptiPharm to make OptiBiotix's
award-winning weight management solution available to a wide range
of customers through major pharmacy and supermarket retailers and
online in over 20 countries. W e are excited to work with such a
well known market leading partner who has the means to
promote its products aggressively ( https://www.soccerex.com/insight/articles/2016/melbourne-victory-net-optislim-deal ) . This deal further expands our access to global markets and we are particularly pleased to have our functional ingredient sold by major retailers in more and more countries around the world creating value for our partners, customers and shareholders. "
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014.
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via Walbrook
below
Cairn Financial Advisers LLP (NOMAD) Tel: 020 7213 0880
Liam Murray / Jo Turner / Ludovico Lazzaretti
finnCap (Broker) Tel: 020 7220 0500
Geoff Nash / Kate Bannatyne (Corporate Finance)
Camille Gochez (Corporate Broking)
goetzpartners securities Limited Tel: 0203 859 7725
Ulrich Kinzel
Walbrook PR Ltd Mob: 07876 741 001
Anna Dunphy
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March
2012, brings science to the development of compounds which modify
the human microbiome - the collective genome of the microbes in the
body - in order to prevent and manage human disease and promote
wellness.
OptiBiotix has an extensive R&D program working with leading
academics in the development of microbial strains, compounds, and
formulations which are used as active ingredients and supplements.
More than twenty international food and healthcare supplement
companies have signed agreements with OptiBiotix to incorporate
their human microbiome modulators into a wide range of food
products and drinks.
OptiBiotix is also developing its own range of consumer
supplements and health products. The Company's current areas of
focus include obesity, cardiovascular health, and diabetes.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCJMMATMTMJBAM
(END) Dow Jones Newswires
March 31, 2020 02:00 ET (06:00 GMT)
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Apr 2024 to May 2024
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From May 2023 to May 2024